ポスター発表H会場

[1-H-P-28] Drug metabolizing activities required for human iPS cell-derived hepatocytes in the ADMET research

^○Tetsuro Araki ^1,3, Norihiko Iwazaki ^2,4, Keisuke Nagata ^2,5, Masato Ohbuchi ^2,5, Hiroyuki Moriguchi ^2,5, Makiko Motoi ^2,6, Raku Shinkyo ^2,6, Sakae Sakamoto ^2,7, Yumiko Iwase ^2,3,4, Naoki Ishiguro ^2,8 (1.Consortium for Safety Assessment using Human iPS Cells / Asahi Kasei Pharma Corporation, 2.Consortium for Safety Assessment using Human iPS Cells, 3.Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association, 4.Mitsubishi Tanabe Pharma Corporation, 5.Astellas Pharma Inc.)